IGF-1LR3
Research use only.
IGF-1 LR3 (Insulin-Like Growth Factor-1 Long Arg3) is a modified analog of naturally occurring IGF-1, engineered for enhanced stability and an extended half-life. It is widely studied in research settings for its role in cell proliferation, differentiation, and anabolic signaling, making it a key compound in studies of growth and tissue development.
Product overview
IGF-1 LR3 is a research-grade peptide consisting of a 83-amino-acid sequence with structural modifications that reduce binding to IGF-binding proteins, increasing its bioavailability and activity in experimental models. Preclinical research associates IGF-1 LR3 with enhanced cellular growth, improved nutrient partitioning, and activation of signaling pathways involved in muscle and tissue development.
Key research features
Cellular growth and proliferation:
IGF-1 LR3 is widely investigated for its ability to stimulate cell growth, division, and differentiation. Research models explore its role in tissue development and regenerative processes.
Anabolic and signaling pathways:
Studies suggest IGF-1 LR3 activates key pathways such as PI3K/Akt and MAPK, supporting research into protein synthesis, nutrient utilization, and cellular adaptation.
Extended activity and bioavailability:
Due to its structural modifications, IGF-1 LR3 demonstrates reduced binding to IGF-binding proteins and prolonged activity, making it valuable for sustained signaling studies in controlled research environments.
IGF-1 LR3 – Suggested Use (Research Context)
Typical Dose: 20–100 mcg per day
Route: Subcutaneous injection
Frequency: Once daily
Duration: As directed by a qualified professional